ClinicalTrials.gg
RecruitingNCT04232787SEA-BrSUpdated Oct 30, 2026

Southeast Asian Brugada Syndrome Cohort

An observational study in Brugada Syndrome, sponsored by Chulalongkorn University. Recruiting at 11 sites in Thailand. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Chulalongkorn University · Observational

How we know

From the registry’s dates

  • Started Jan 2016; still recruiting 10 years 9 months later.
Updated Oct 30, 2026Now RecruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Sex
All
01

Study summary

Brugada syndrome (BrS) is the leading cause of sudden death in young Asian adults including Thailand. This syndrome may be hereditary and involve mutations in certain genes. Aim of the study is to identify the relationship between genetic variants and the diagnosis/clinical severity of patients with BrS.

Read the detailed description

This cohort study recruits BrS patients with confirmed Brugada type 1 ECG and healthy volunteers in Thailand. Data collection consists of demographic, clinical data, ECG and blood sample for genetic studies. Genotyping was done by whole genome sequencing and SNP array then compared between cases and controls. Each BrS patient will be followed up prospectively for symptoms and AICD shock. Subsequently, the study will analyze relationship between genetic variants and clinical data against clinical severity of BrS patients.

02

Conditions studied

  • Brugada Syndrome

Browse trials for

Keywords

  • Brugada Syndrome
  • Genetics
  • Epidemiology
  • Thai
  • Southeast Asia
03

In context

Brugada Syndrome

53 studies on the registry are indexed under Brugada Syndrome; 19 are open to participants now.

This study's planned enrollment of 750 is above the median of 155 across 34 observational studies indexed under Brugada Syndrome.

Browse Brugada Syndrome studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 323 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Thai Brugada syndrome patients and healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Thai nationality
  • The patient has at least one of confirmed Brugada type 1 in at least one of right precordial leads (v1 or v2) with or without pharmacologic provocative testing. The confirmed ECG is standard 12 lead ECG or Brugada lead

Exclusion criteria

Exclusion Criteria:

  • The patient has other cardiac diseases such as ischemic heart disease, valvular heart disease, congenital heart disease, myocarditis and pericarditis
  • The patient has type 2 or type 3 Brugada without type 1 ECG during pharmacologic provocative testing and/or Brugada lead
  • The patient had one time of Brugada type 1 ECG during drug use without reproducibility
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Target follow-up
7 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case

    Thai patients with diagnosed Brugada syndrome by confirmed Brugada type 1 ECG.

  • Control

    Healthy volunteers without Brugada marker from ECG.

06

What researchers measure

Primary outcomes

  1. Relationship between genetic variants and Brugada syndrome (Brugada syndrome phenotype)

    Case-Control study of genetic variants in BrS cases vs controls. Genetic study was done by whole genome sequencing and SNP array. Association analysis assessed by polygenic risk score and regression coefficients.

    Time frame: 7 years

Secondary outcomes

  1. Natural history of Brugada syndrome (survival from arrhythmic events)

    Cohort study to followed up BrS patients with or with arrhythmic events which assessed by survival curve analysis.

    Time frame: 7 years

  2. Epidemiology of Brugada syndrome

    To study prevalence of Brugada syndrome in Thailand.

    Time frame: 7 years

07

Study locations

11 of 11 sites recruiting
  • Bangkok Hospital
    Bangkok, Bangkok 10310, Thailand
    Recruiting
    • Apichai Khongphatthanayothin, MD · Contactapichaik@yahoo.com · 66891555545
    • Apichai Khongphatthanayothin, MD · Principal investigator
  • Siriraj Hospital, Mahidol University
    Bangkok Noi, Bangkok 10700, Thailand
    Recruiting
    • Rungroj Krittayaphong, MD · Contactrungroj.kri@mahidol.ac.th · 66818059992
    • Rungroj Krittayaphong, MD · Principal investigator
  • Vajira Hospital
    Dusit, Bangkok 10300, Thailand
    Recruiting
    • Thaveekiat Vasavakul, MD · Contactthaveekiat@hotmail.com · 66814515421
    • Thaveekiat Vasavakul, MD · Principal investigator
  • Chulalongkorn University
    Pathum Wan, Bangkok 10330, Thailand
    Recruiting
    • Apichai Khongphatthanayothin, MD · Contactapichaik@yahoo.com · 66891555545
    • Pharawee Wandee, BSc · Contactbrugadaproject@gmail.com · 66944174331
    • Somchai Prechawat, MD · Sub investigator
    • Sanchai Payungporn, PhD · Sub investigator
    • Duangdao Wichadakul, PhD · Sub investigator
    • Natawut Nupairoj, PhD · Sub investigator
    • Krerk Piromsopa, PhD · Sub investigator
    • Saran Vardhanabhuti, PhD · Sub investigator
    • Duangkamon Ittipcharoen, BSc · Sub investigator
    • Nitinan Chimparlee, MD · Sub investigator
    • John Mauleekoonphairoj, MSc · Sub investigator
    • Boosamas Sutjaporn, BNS · Sub investigator
    • Pharawee Wandee, BSc · Sub investigator
  • Faculty of Medicine Ramathibodi Hospital, Mahidol University
    Ratchathewi, Bangkok 10400, Thailand
    Recruiting
    • Tachapong Ngamukos, MD · Contacttetng@mahidol.ac.th · 66819241527
    • Tachapong Ngamukos, MD · Principal investigator
    • Montawatt Amnueypol, MD · Sub investigator
  • Bhumibol Adulyadej RTAF Hospital
    Sai Mai, Bangkok 10220, Thailand
    Recruiting
  • Bumrungrad International Hospital
    Vadhana, Bangkok 10110, Thailand
    Recruiting
  • Pacific Rim Electrophysiology Research Institute Data Coordinating Center
    Vadhana, Bangkok 10110, Thailand
    Recruiting
  • Queen Sirikit Heart Center of the Northeast
    Khon Kaen, Changwat Khon Kaen 40002, Thailand
    Recruiting
    • Pattarapong Makarawate, MD · Contactpattarapong@kku.ac.th · 66816614751
    • Pattarapong Makarawate, MD · Principal investigator
    • Dujdao Sahasatas, MD · Sub investigator
  • Central Chest Hospital
    Nonthaburi, Changwat Nonthaburi 11000, Thailand
    Recruiting
    • Alisara Anannab, MD · Contactalicera_24@hotmail.com · 66819380010
    • Alisara Anannab, MD · Principal investigator
  • Faculty of Medicine, Chiang Mai University
    Chiang Mai, Chiang Mai 50200, Thailand
    Recruiting
    • Wanwarang Wongcharoen, MD · Contactbwanwarang@yahoo.com · 66897001604
    • Wanwarang Wongcharoen, MD · Principal investigator
08

References and documents

Publications

  • Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation. 2012 Jan 31;125(4):620-37. doi: 10.1161/CIRCULATIONAHA.111.023838. No abstract available. PubMed 22294707 ↗
  • Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec;10(12):1932-63. doi: 10.1016/j.hrthm.2013.05.014. Epub 2013 Aug 30. No abstract available. PubMed 24011539 ↗
  • Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, Tunsanga K, Kuasirikul S, Malasit P, Tansupasawadikul S, Tatsanavivat P. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997 Oct 21;96(8):2595-600. doi: 10.1161/01.cir.96.8.2595. PubMed 9355899 ↗
  • Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Verkerk AO, Schwartz PJ, Crotti L, Dagradi F, Guicheney P, Fressart V, Leenhardt A, Antzelevitch C, Bartkowiak S, Borggrefe M, Schimpf R, Schulze-Bahr E, Zumhagen S, Behr ER, Bastiaenen R, Tfelt-Hansen J, Olesen MS, Kaab S, Beckmann BM, Weeke P, Watanabe H, Endo N, Minamino T, Horie M, Ohno S, Hasegawa K, Makita N, Nogami A, Shimizu W, Aiba T, Froguel P, Balkau B, Lantieri O, Torchio M, Wiese C, Weber D, Wolswinkel R, Coronel R, Boukens BJ, Bezieau S, Charpentier E, Chatel S, Despres A, Gros F, Kyndt F, Lecointe S, Lindenbaum P, Portero V, Violleau J, Gessler M, Tan HL, Roden DM, Christoffels VM, Le Marec H, Wilde AA, Probst V, Schott JJ, Dina C, Redon R. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013 Sep;45(9):1044-9. doi: 10.1038/ng.2712. Epub 2013 Jul 21. PubMed 23872634 ↗
  • Chimparlee N, Prechawat S, Khongphatthanayothin A, Mauleekoonphairoj J, Lekchuensakul S, Wongcharoen W, Makarawate P, Sahasatas D, Krittayaphong R, Amnueypol M, Anannab A, Ngarmukos T, Vardhanabhuti S, Sutjaporn B, Wandee P, Veerakul G, Bezzina CR, Poovorawan Y, Nademanee K. Clinical Characteristics of SCN5A p.R965C Carriers: A Common Founder Variant Predisposing to Brugada Syndrome in Thailand. Circ Genom Precis Med. 2021 Jun;14(3):e003229. doi: 10.1161/CIRCGEN.120.003229. Epub 2021 Jun 7. No abstract available. PubMed 34092119 ↗
  • Makarawate P, Glinge C, Khongphatthanayothin A, Walsh R, Mauleekoonphairoj J, Amnueypol M, Prechawat S, Wongcharoen W, Krittayaphong R, Anannab A, Lichtner P, Meitinger T, Tjong FVY, Lieve KVV, Amin AS, Sahasatas D, Ngarmukos T, Wichadakul D, Payungporn S, Sutjaporn B, Wandee P, Poovorawan Y, Tfelt-Hansen J, Tanck MWT, Tadros R, Wilde AAM, Bezzina CR, Veerakul G, Nademanee K. Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand. Heart Rhythm. 2020 Dec;17(12):2145-2153. doi: 10.1016/j.hrthm.2020.06.027. Epub 2020 Jun 30. PubMed 32619740 ↗

Individual participant data

Plan to share: Yes — Medical journals, abstract submissions and results database

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2016 (actual). Primary completion is estimated for Jan 2031, 179 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jan 2021 → Jan 2031 and completion Jan 2023 → Jan 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2020
First posted
Jan 18, 2020
StartActual
Jan 28, 2016
Primary completionEst.
Jan 5, 2031was Jan 2021
CompletionEst.
Jan 5, 2031was Jan 2023
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Oct 30, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (6 Thailand)
  • Bangkok Hospital · Bangkok, Thailand
  • Bumrungrad International Hospital · Vadhana, Thailand
  • Pacific Rim Electrophysiology Research Institute Data Coordinating Center · Vadhana, Thailand
  • Queen Sirikit Heart Center of the Northeast · Khon Kaen, Thailand
  • Central Chest Hospital · Nonthaburi, Thailand
  • Faculty of Medicine, Chiang Mai University · Chiang Mai, Thailand
Show 6 removed
  • Bumrungrad International Hospital · Watthana, Thailand
  • Pacific Rim Electrophysiology Research Institute Data Coordinating Center · Watthana, Thailand
  • Bangkok Hospital · Bangkok, Thailand
  • Faculty of Medicine, Chiang Mai University · Chiang Mai, Thailand
  • Queen Sirikit Heart Center of the Northeast · Khon Kaen, Thailand
  • Central Chest Hospital · Nonthaburi, Thailand
Oct 30, 2026
Primary completion
Jan 2021→Jan 5, 2031
Oct 30, 2026
Study completion
Jan 2023→Jan 5, 2031
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Status unknown→Recruiting
    6 sites added, 6 sites removed
    Show 6 added (6 Thailand)
    • Bangkok Hospital · Bangkok, Thailand
    • Bumrungrad International Hospital · Vadhana, Thailand
    • Pacific Rim Electrophysiology Research Institute Data Coordinating Center · Vadhana, Thailand
    • Queen Sirikit Heart Center of the Northeast · Khon Kaen, Thailand
    • Central Chest Hospital · Nonthaburi, Thailand
    • Faculty of Medicine, Chiang Mai University · Chiang Mai, Thailand
    Show 6 removed
    • Bumrungrad International Hospital · Watthana, Thailand
    • Pacific Rim Electrophysiology Research Institute Data Coordinating Center · Watthana, Thailand
    • Bangkok Hospital · Bangkok, Thailand
    • Faculty of Medicine, Chiang Mai University · Chiang Mai, Thailand
    • Queen Sirikit Heart Center of the Northeast · Khon Kaen, Thailand
    • Central Chest Hospital · Nonthaburi, Thailand
    Primary completion Jan 2021→Jan 5, 2031
    Study completion Jan 2023→Jan 5, 2031
    + 4 other changes: index terms, verification date, responsible party and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04232787
Collaborators
National Research Council of Thailand, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Responsible party
Apichai Khongphatthanayothin, MD (Principal Investigator, Professor of Pediatrics, Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University) — Principal investigator
First posted
Jan 18, 2020
Start date
Jan 28, 2016
Primary completion
Jan 5, 2031 (estimated)
Completion
Jan 5, 2031 (estimated)
Last update
Oct 30, 2026

Study contacts

Apichai Khongphatthanayothin, MD
Contact
apichaik@yahoo.com
66891555545
Pharawee Wandee, BSc
Contact
brugadaproject@gmail.com
66944174331
Koonlawee Nademanee, MD
study chair · Chulalongkorn University
Yong Poovorawan, MD
study director · Chulalongkorn University
Apichai Khongphatthanayothin, MD
principal investigator · Chulalongkorn University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion